PolyTherics receives new investment to accelerate growth
PolyTherics is issuing new shares up to an aggregate value of
The enlarged PolyTherics group will leverage its combined portfolio of proprietary and complementary technologies and services to address key needs in biopharmaceutical development. The combined portfolio will include conjugation technologies to produce more stable and homogeneous antibody drug conjugates, technologies to optimise the pharmacokinetics of biologics, technologies for immunogenicity screening, technologies to re-engineer antibodies and proteins to reduce their immunogenicity, and cell line development technologies. The group has a strong client base in the biotechnology and pharmaceutical industry, including many of the world's top companies.
The expanded offering will provide the PolyTherics group with a broad technology platform for growth and a solid financial base with sustainable revenue streams over the short-, medium- and longer-term. Growing revenues are derived from the services offered by Antitope and feasibility studies undertaken by PolyTherics and from pre-defined milestone payments under licence agreements for the group's conjugation and de-immunisation technologies. These licences also have the potential to provide future royalties on a portfolio of products which utilise the group's proprietary technologies.
PolyTherics provides technology solutions to enable the development of better biopharmaceuticals and offers a portfolio of proprietary and complementary technologies and services to address key needs in biopharmaceutical development.
PolyTherics' portfolio includes proprietary site-specific conjugation technologies and novel polymers for optimising the therapeutic properties of biopharmaceuticals, including ThioBridge(TM) for more stable and homogeneous antibody drug conjugates, TheraPEG(TM), CyPEG(TM), HiPEG(TM) and PolyPEG(TM) for optimisation of the pharmacokinetics of biologics and GlycoPol(TM) for targeted delivery.
The PolyTherics group will provide immunogenicity testing, antibody humanisation and protein re-engineering technologies through its Antitope subsidiary, including EpiScreen(TM), Composite Human Antibody(TM), Composite Protein(TM) and Composite CHO(TM). These technologies have been used to develop several therapeutic antibody candidates that are advancing through clinical trials. The group provides its services and technologies to an international client base that includes many of the world's leading biotechnology and pharmaceutical companies.
PolyTherics is a privately owned
For more information contact:
Most Popular Stories
- Updates on Everglades' Stranded Pilot Whales
- Hezbollah Chief's Assassination Claimed by Sunni Group
- Stolen Cobalt-60 Recovered in Mexico
- Wind Power and Wildlife Can Coexist
- Ford Mustang Still Packs Power
- NSA Tracks 5 Billion Cellphone Records a Day
- Allstate Seeks to Invest in Minority Firms
- Sarmiento to Handle Greeley Latin Ops
- First-time Jobless Claims Drop Below 300,000
- White House Pushes to Extend Unemployment Benefits